Biomanufacturing Consortium (BioMAN)

The Biomanufacturing consortium (BioMAN) seeks to develop new knowledge, science, technologies, and strategies that advance the manufacture and global delivery of high quality biopharmaceuticals. As a neutral third party, MIT provides a pre-competitive environment where stake-holders can work together to develop improvements in biomanufacturing.

BioMAN connects industry, academia, and government to identify challenges and best practices in biologics manufacturing by hosting Workshops and Summits and by conducting projects related to the BioMAN Workstreams. BioMAN leverages the strengths of MIT faculty in the schools of Science, Engineering, and Management in all of these activities.


Provide a safe haven for collaborative, pre-competitive research among industry, academia, and government.

Provide a forum for companies to benchmark and identify best industry practices on the manufacture of existing and emerging therapies and be exposed to the novel technologies and capabilities of MIT most relevant to the biotherapeutics industry.

Increase awareness at MIT of unmet needs and opportunities in bioprocessing that map to faculty expertise.

Facilitate cross- and interdisciplinary research leveraging MIT’s world class expertise in engineering, science, economics, and business strategy to address challenges to the manufacturing and delivery of biologics.

Create impactful educational experiences to expand the reach of biomanufacturing education and to better connect theoretical concepts to real-world applications.


BioMAN explores science, technology, business and policy issues related to its biomanufacturing Workstreams and defines collaborative research projects that advance the field.

Data Analytics in Biomanufacturing

BioMAN is exploring the application of advanced analytics to the process of manufacturing biotherapeutics with the expected benefit of improving efficiency, as well as reducing time and effort, to product high quality products.

Biomanufacturing Challenges for Cell and Gene Therapy Products

Cell and gene therapies have great potential but face significant manufacturing challenges. BioMAN activities are exploring the current state of the art as well as new technologies and solutions to meet these challenges.

Product Quality Control in Biomanufacturing

BioMAN is exploring new technologies and approaches to measure important product quality attributes of both protein and cell therapies.

Vaccine Manufacturing

BioMAN, in collaboration with University College London, hosts an annual Vaccine Process and Development Workshop allowing attendees to learn about cutting edge vaccine manufacturing approaches.


Competency Model for Biomanufacturing Data Scientists

BioMAN members are collaborating to define the competency requirements for data scientists in biomanufacturing. This model can be used to facilitate curriculum development in academic institutions and guide development of training programs in industry.

Aggregation of Raw Material Data for Predictive Analysis in Biomanufacturing

This project demonstrates the value of multi-company collaboration in application of data analytics to aggregated raw material data, using an appropriate case study.

For more information or to join BioMAN, please contact:

Stacy L. Springs, PhD
Executive Director, Biomanufacturing Program (BioMAN)
Executive Director, Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB)
Phone: 617-253-3084